Patents by Inventor Yiyun Cheng

Yiyun Cheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11077206
    Abstract: A composition for gene therapy or transfection includes nucleic acid, natural polyphenol, and cationic molecules. There are several phenolic hydroxyl groups in the natural polyphenol, so as to eliminate free radicals, prevent cancer, fight inflammation, and provide antioxidants feature. Compared with the delivery of cationic molecules alone, the composition can significantly improve the transfection efficiency by about 60-70%, reduce the dose of effective transfection of cationic molecules by about 20 times, thereby reducing the toxicity of transfection and showing better organism compatibility. The composition of the present invention does not introduce other chemical reagents, does not require synthesis, has high biosafety, and can efficiently and safely deliver a plurality of nucleic acid molecules into cells. The composition can be used as a highly effective and low-toxicity nucleic acid drug in the treatment of gene-related diseases, and has good medicinal value.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: August 3, 2021
    Assignee: SHANGHAI CHANGZHENG HOSPITAL
    Inventors: Jianru Xiao, Wanwan Shen, Xiaopan Cai, Yiyun Cheng
  • Publication number: 20190290779
    Abstract: A composition for gene therapy or transfection includes nucleic acid, natural polyphenol, and cationic molecules. There are several phenolic hydroxyl groups in the natural polyphenol, so as to eliminate free radicals, prevent cancer, fight inflammation, and provide antioxidants feature. Compared with the delivery of cationic molecules alone, the composition can significantly improve the transfection efficiency by about 60-70%, reduce the dose of effective transfection of cationic molecules by about 20 times, thereby reducing the toxicity of transfection and showing better organism compatibility. The composition of the present invention does not introduce other chemical reagents, does not require synthesis, has high biosafety, and can efficiently and safely deliver a plurality of nucleic acid molecules into cells. The composition can be used as a highly effective and low-toxicity nucleic acid drug in the treatment of gene-related diseases, and has good medicinal value.
    Type: Application
    Filed: September 6, 2018
    Publication date: September 26, 2019
    Applicant: SHANGHAI CHANGZHENG HOSSPITA
    Inventors: Jianru Xiao, Wanwan Shen, Xiaopan Cai, Yiyun Cheng